

# Novartis Patient Assistance Foundation

**Committed to providing access to Novartis medications for those most in need.**

NPAF is an independent, 501(c)(3) non-profit, non-commercial entity. Patients who cannot afford the cost of their Novartis medication may be eligible to receive them from NPAF at no cost.

## To be eligible, patients must:

- Reside in the United States or a U.S. Territory
- Be treated by a licensed U.S. healthcare provider on an outpatient basis
- Meet income and affordability guidelines\*

## How it works:

- Patients are enrolled for up to 12 months
- Annual re-enrollment is required
- Enrolled patients get Novartis medication at no cost

*\*See below for more information about eligibility. Criteria vary by product.*

---

**Select your medication(s) from the list below, review the product-specific requirements for each medication(s), and follow the directions provided to apply.**

Adakveo® (crizanlizumab-tmca)

### Income Limits

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### Application Instructions

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Afinitor® (everolimus)

### Income Limits

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### Application Instructions

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282

7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Afinitor Disperz® (everolimus suspension)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282

7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Beovu® (brolucizumab-dblI) Injection

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New & Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Coartem® (artemether and lumefantrine)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New & Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Cosentyx® (secukinumab)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New & Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Entresto™ (sacubitril/valsartan)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New & Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Fabhalta® (iptacopan)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [View eligibility \(PDF 0.2 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply through Novartis Patient Support at 1 833 993 2242 or visit the website at [www.Fabhalta.com](http://www.Fabhalta.com). Prescribers need to complete the Fabhalta Start Form found on [www.fabhalta-hcp.com](http://www.fabhalta-hcp.com) and send the form to Novartis Patient Support, fax number: 1 877 443 2242.

Gilenya® (fingolimod)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New & Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Ilaris® (canakinumab)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New & Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Jadenu ® (deferasirox)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282

7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Jadenu® Sprinkle (deferasirox) granules

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282

7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Kesimpta® (ofatumumab)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply through the Alongside™ KESIMPTA at 1 855 537 4678 or visit the website at [www.Kesimpta.com](http://www.Kesimpta.com)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Kisqali® (ribociclib)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply through Novartis Patient Support at 1 866 433 8000 or visit the website at [www.kisqali.com](http://www.kisqali.com). Prescribers need to complete the Kisqali Start Form found on [www.kisqali-hcp.com](http://www.kisqali-hcp.com) and send the form to Novartis Patient Support, fax number: 1 800 414 3518.

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Leqvio®

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply through the Leqvio® Service Center at 1 833-LEQVIO2 (833 537 8462) or visit the website at [www.Leqvio.com](http://www.Leqvio.com). Prescribers need to complete the Leqvio Service Center Start Form and follow submission instructions found at [www.Leqviohcp.com](http://www.Leqviohcp.com).

For Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Lutathera® (lutetium Lu 177 dotatate)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New & Reenrolling Patients: Apply through RLT Novartis Patient Support 1 844 638 7222. Prescribers use Program Enrollment Form: [Novartis-PatientSupport.com/RLT](http://Novartis-PatientSupport.com/RLT)

Mayzent®

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply through the Mayzent® patient support program at 1 877 629 9368 or visit the website at [www.Mayzent.com](http://www.Mayzent.com).

For Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Mekinist® (trametinib)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630  
[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Piqray® (alpelisib)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Pluvicto® (177Lu-PSMA-617)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New & Reenrolling Patients: Apply through RLT Novartis Patient Support 1 844 638 7222.

Prescribers use Program Enrollment Form: [Novartis-PatientSupport.com/RLT](https://Novartis-PatientSupport.com/RLT)

Promacta® (eltrombopag)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

RYDAPT® (midostaurin)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

SANDOSTATIN LAR® DEPOT (octreotide acetate) 6/12

## Income Limits

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

## Application Instructions

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Scemblix® (asciminib) Tablets

## Income Limits

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

## Application Instructions

For New Patients: Apply through Novartis Patient Support at 1 866 433 8000 or visit the website at [www.scemblix.com](http://www.scemblix.com). Prescribers need to complete Scemblix Start Form found on [www.scemblix-hcp.com](http://www.scemblix-hcp.com) and send the form to Novartis Patient Support, fax number: 1 800 368 5564.

For Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Tabrecta™ (capmatinib)

## Income Limits

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

## Application Instructions

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form  
[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Tafinlar® (dabrafenib)

## Income Limits

To be eligible, you must meet the income guidelines, which may vary by product and household size. Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

## Application Instructions

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Tasigna® (nilotinib)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Tykerb® (lapatinib)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Vijoice® (alpelisib)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### **Application Instructions**

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

Votrient® (pazopanib)

### **Income Limits**

To be eligible, you must meet the income guidelines, which may vary by product and household size.



Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### Application Instructions

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

ZYKADIA® (ceritinib)

### Income Limits

To be eligible, you must meet the income guidelines, which may vary by product and household size.

Please click on the link to see if you may qualify. [Check eligibility \(PDF 0.3 MB\)](#)

---

### Application Instructions

For New Patients: Apply online through the Patient Assistance Now Oncology (PANO) program 1 800 282 7630

[Patient portal](#) | [Prescriber portal](#)

For Reenrolling Patients: Download the NPAF application form

[English \(PDF 0.2 MB\)](#) | [Spanish \(PDF 0.2 MB\)](#)

---

**Source URL:** <https://qa1.novartis.us/patients-and-caregivers/patient-assistance/patient-assistance-foundation-enrollment>

### List of links present in page

1. <https://qa1.novartis.us/patients-and-caregivers/patient-assistance/patient-assistance-foundation-enrollment>
2. [https://qa1.novartis.us/sites/novartis\\_us/files/adakveo-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/adakveo-fpl-grid-04.01.2024.pdf)
3. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
4. <https://www.hcp.novartis.com/access/>
5. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
6. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
7. [https://qa1.novartis.us/sites/novartis\\_us/files/afinitor-disperz-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/afinitor-disperz-fpl-grid-04.01.2024.pdf)
8. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
9. <https://www.hcp.novartis.com/access/>
10. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
11. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
12. [https://qa1.novartis.us/sites/novartis\\_us/files/afinitor-disperz-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/afinitor-disperz-fpl-grid-04.01.2024.pdf)
13. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
14. <https://www.hcp.novartis.com/access/>
15. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
16. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
17. [https://qa1.novartis.us/sites/novartis\\_us/files/beovu-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/beovu-fpl-grid-04.01.2024.pdf)
18. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
19. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
20. [https://qa1.novartis.us/sites/novartis\\_us/files/coartem-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/coartem-fpl-grid-04.01.2024.pdf)
21. [https://qa1.novartis.us/us-en/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/us-en/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
22. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)

23. [https://qa1.novartis.us/sites/novartis\\_us/files/cosentyx-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/cosentyx-fpl-grid-04.01.2024.pdf)
24. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
25. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
26. [https://qa1.novartis.us/sites/novartis\\_us/files/entresto-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/entresto-fpl-grid-04.01.2024.pdf)
27. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
28. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
29. [https://qa1.novartis.us/sites/novartis\\_us/files/fabhalta-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/fabhalta-fpl-grid-04.01.2024.pdf)
30. <http://www.fabhalta.com/>
31. <http://www.fabhalta-hcp.com/>
32. [https://qa1.novartis.us/sites/novartis\\_us/files/gilenya-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/gilenya-fpl-grid-04.01.2024.pdf)
33. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
34. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
35. [https://qa1.novartis.us/sites/novartis\\_us/files/ilaris-fpl-grid-09.25.2023\\_0.pdf](https://qa1.novartis.us/sites/novartis_us/files/ilaris-fpl-grid-09.25.2023_0.pdf)
36. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
37. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
38. [https://qa1.novartis.us/sites/novartis\\_us/files/jadenu-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/jadenu-fpl-grid-04.01.2024.pdf)
39. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
40. <https://www.hcp.novartis.com/access/>
41. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
42. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
43. [https://qa1.novartis.us/sites/novartis\\_us/files/jadenu-sprinkles-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/jadenu-sprinkles-fpl-grid-04.01.2024.pdf)
44. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
45. <https://www.hcp.novartis.com/access/>
46. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
47. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
48. [https://qa1.novartis.us/sites/novartis\\_us/files/kesimpta-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/kesimpta-fpl-grid-04.01.2024.pdf)
49. <https://www.kesimpta.com/>
50. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
51. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
52. [https://qa1.novartis.us/sites/novartis\\_us/files/kisqali-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/kisqali-fpl-grid-04.01.2024.pdf)
53. <http://www.kisqali.com>
54. <http://www.kisqali-hcp.com>
55. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
56. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
57. [https://qa1.novartis.us/sites/novartis\\_us/files/leqvio-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/leqvio-fpl-grid-04.01.2024.pdf)
58. <http://www.leqvio.com/>
59. <https://www.leqviohcp.com/>
60. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
61. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
62. [https://qa1.novartis.us/sites/novartis\\_us/files/lutathera-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/lutathera-fpl-grid-04.01.2024.pdf)
63. <http://novartis-patientsupport.com/RLT>
64. [https://qa1.novartis.us/sites/novartis\\_us/files/mayzent-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/mayzent-fpl-grid-04.01.2024.pdf)
65. <https://www.mayzent.com/>
66. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
67. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
68. [https://qa1.novartis.us/sites/novartis\\_us/files/mekinist-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/mekinist-fpl-grid-04.01.2024.pdf)
69. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
70. <https://www.hcp.novartis.com/access/>
71. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
72. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
73. [https://qa1.novartis.us/sites/novartis\\_us/files/piqray-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/piqray-fpl-grid-04.01.2024.pdf)
74. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
75. <https://www.hcp.novartis.com/access/>
76. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)

77. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
78. [https://qa1.novartis.us/sites/novartis\\_us/files/pluvicto-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/pluvicto-fpl-grid-04.01.2024.pdf)
79. <http://novartis-patientsupport.com/RLT>
80. [https://qa1.novartis.us/sites/novartis\\_us/files/promacta-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/promacta-fpl-grid-04.01.2024.pdf)
81. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
82. <https://www.hcp.novartis.com/access/>
83. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
84. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
85. [https://qa1.novartis.us/sites/novartis\\_us/files/rydapt-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/rydapt-fpl-grid-04.01.2024.pdf)
86. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
87. <https://www.hcp.novartis.com/access/>
88. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
89. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
90. [https://qa1.novartis.us/sites/novartis\\_us/files/sandostatin-lar-depot-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/sandostatin-lar-depot-fpl-grid-04.01.2024.pdf)
91. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
92. <https://www.hcp.novartis.com/access/>
93. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
94. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
95. [https://qa1.novartis.us/sites/novartis\\_us/files/scemblix-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/scemblix-fpl-grid-04.01.2024.pdf)
96. <http://www.scemblix.com>
97. <http://www.scemblix-hcp.com>
98. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
99. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
100. [https://qa1.novartis.us/sites/novartis\\_us/files/tabrecta-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/tabrecta-fpl-grid-04.01.2024.pdf)
101. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
102. <https://www.hcp.novartis.com/access/>
103. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
104. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
105. [https://qa1.novartis.us/sites/novartis\\_us/files/tafinlar-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/tafinlar-fpl-grid-04.01.2024.pdf)
106. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
107. <https://www.hcp.novartis.com/access/>
108. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
109. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
110. [https://qa1.novartis.us/sites/novartis\\_us/files/tasigna-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/tasigna-fpl-grid-04.01.2024.pdf)
111. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
112. <https://www.hcp.novartis.com/access/>
113. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
114. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
115. [https://qa1.novartis.us/sites/novartis\\_us/files/tykerb-fpl-grid-09.25.2023\\_0.pdf](https://qa1.novartis.us/sites/novartis_us/files/tykerb-fpl-grid-09.25.2023_0.pdf)
116. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
117. <https://www.hcp.novartis.com/access/>
118. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
119. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
120. [https://qa1.novartis.us/sites/novartis\\_us/files/vijoice-fpl-grid-09.25.2023\\_0.pdf](https://qa1.novartis.us/sites/novartis_us/files/vijoice-fpl-grid-09.25.2023_0.pdf)
121. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
122. <https://www.hcp.novartis.com/access/>
123. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
124. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
125. [https://qa1.novartis.us/sites/novartis\\_us/files/votrient-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/votrient-fpl-grid-04.01.2024.pdf)
126. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
127. <https://www.hcp.novartis.com/access/>
128. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
129. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)
130. [https://qa1.novartis.us/sites/novartis\\_us/files/zykadia-fpl-grid-04.01.2024.pdf](https://qa1.novartis.us/sites/novartis_us/files/zykadia-fpl-grid-04.01.2024.pdf)

131. <https://www.patient.novartisoncology.com/financial-assistance/pano/>
132. <https://www.hcp.novartis.com/access/>
133. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-english.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-english.pdf)
134. [https://qa1.novartis.us/sites/novartis\\_us/files/npaf-digital-start-form-spanish.pdf](https://qa1.novartis.us/sites/novartis_us/files/npaf-digital-start-form-spanish.pdf)